Brief: Arcutis Canada Says Health Canada Approves ZORYVE Foam 0.3% For Scalp, Body Psoriasis For Adults & Adolescents 12 & Older
13/11/2025 13:22
Nov 13 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O: ARCUTIS CANADA: HEALTH CANADA APPROVES ZORYVE FOAM 0.3% FOR SCALP, BODY PSORIASIS FOR ADULTS & ADOLESCENTS AGES 12 & OLDER CANADA NEWSWIRE ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf